Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [41] Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
    Iwamoto, Y.
    Tajima, N.
    Kadowaki, T.
    Nonaka, K.
    Taniguchi, T.
    Nishii, M.
    Ferreira, J. C. Arjona
    Amatruda, J. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (07): : 613 - 622
  • [42] Effect of Pioglitazone on Serum Uric Acid Levels in Newly Diagnosed, Drug-Naive Patients with Type 2 Diabetes
    Kutoh, Eiji
    Hori, Tadataka
    ENDOCRINE RESEARCH, 2013, 38 (03) : 151 - 159
  • [43] Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database
    Morita, Yohei
    Murayama, Hiroki
    Odawara, Masato
    Bauer, Melissa
    DIABETOLOGY & METABOLIC SYNDROME, 2019, 11 (01):
  • [44] Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naive Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
    Ito, Daisuke
    Inoue, Kazuyuki
    Saito, Daigo
    Hamaguchi, Keiko
    Kaneko, Kimie
    Sumita, Takashi
    Inukai, Kouichi
    Inoue, Ikuo
    Shimada, Akira
    DIABETES THERAPY, 2021, 12 (12) : 3201 - 3215
  • [45] Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
    Akira Imamura
    Masahito Kusunoki
    Shinya Ueda
    Nobuya Hayashi
    Yasuhiko Imai
    Diabetes Therapy, 2013, 4 : 41 - 49
  • [46] Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
    Imamura, Akira
    Kusunoki, Masahito
    Ueda, Shinya
    Hayashi, Nobuya
    Imai, Yasuhiko
    DIABETES THERAPY, 2013, 4 (01) : 41 - 49
  • [47] Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes
    Stenlof, K.
    Rossner, S.
    Vercruysse, F.
    Kumar, A.
    Fitchet, M.
    Sjostrom, L.
    DIABETES OBESITY & METABOLISM, 2007, 9 (03): : 360 - 368
  • [48] Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database
    Yohei Morita
    Hiroki Murayama
    Masato Odawara
    Melissa Bauer
    Diabetology & Metabolic Syndrome, 11
  • [49] The effect of topiramate on hepatic fat content in obese subjects with drug-naive type 2 diabetes
    Lonn, L
    Brandberg, J
    Vercruysse, F
    Kumar, A
    Fitchet, M
    Sjostrom, L
    Stenlof, K
    OBESITY RESEARCH, 2004, 12 : A45 - A46